CRTX News and Press, Cortexyme Inc. From 12/24/21

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Shorted stocks continue to be of interest to retail traders looking for the next big day trade and we’re diving into some top candidates! Source: Shutterstock We’re pulling our short stock data from Twi...

CRTX reported partially promising results on October 26, 2021, which have been perceived as a complete failure by the market. Adding the pressure of the recent sell-off in biotech, the stock has hit a year low. CRTX has given investors new hope with a new drug candidate. Drugs...

Short squeezes can deliver enormous returns for investors in the blink of an eye. Several so-called "meme stocks" generated jaw-dropping gains for investors earlier this year due to this phenomenon. The mechanics of a short squeeze are fairly straightforward. Short-sellers, or inves...

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...

Cortexyme, Inc. (Nasdaq: CRTX) announced that Casey Lynch, chief executive officer, co-founder, and chair, will participate in a fireside chat at the 4 th Annual Evercore ISI HealthCONx Conference taking place virtually on Tuesday, November 30, 2021, beginning at 1:25 p.m. Eastern T...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips After eleven or so months you may be done with GameStop (NYSE: GME ). And these days that’s increasingly the case for GME stock and its former army of bears. Source: quietbits / Shutterstock.com But is th...

The GAIN trial failed to meet its primary endpoints in the broader population of patients with mild to moderate Alzheimer’s disease. Cortexyme presented data suggesting a pre-specified subset of patients with Pg DNA in their saliva can benefit from treatment with atuzaginstat. ...

Cortexyme (NASDAQ:CRTX) announced additional topline data from its Phase 2/3 GAIN Trial to indicate that its experimental therapy atuzaginstat slowed the cognitive decline in a prespecified group of Alzheimer’s patients. However, as previously disclosed by the company, for the overall ...

Evidence supports P. gingivalis as a driver of Alzheimer’s in easily identified patient population Successful identification of target population and therapeutic dose inform next steps Cortexyme, Inc. (Nasdaq: CRTX) will present additional data from its Phase ...